前列腺癌全盆腔调强放疗患者报告肠道毒性:肠管剂量体积效应首次量化
本研究基于206例前列腺癌全盆腔调强放疗患者,分析肠道剂量体积参数与患者报告肠道症状的关系。仅稀便症状与剂量体积相关,高风险DVH形状(V20>470cc、V30>245cc、V42>110cc)与稀便风险显著相关(OR 9.3),年龄较大为保护因素(OR 0.94)。限制肠管剂量可能降低稀便风险。
要点
- 仅稀便(ΔIBDQ5≥3)与肠管剂量体积参数相关,其余症状无预测参数。
- 高风险DVH形状(V20>470cc、V30>245cc、V42>110cc)使稀便风险增加(OR 9.3)。
- 年龄较大为保护因素(OR 0.94),年轻患者稀便风险更高。
核心结论
- 限制肠管剂量体积可能降低全盆腔调强放疗后稀便风险,年轻患者风险更高。
研究设计与样本
- 回顾性分析206例前列腺癌全盆腔调强放疗患者,盆腔淋巴结中位剂量51.8Gy(范围50.4-54.4Gy,1.7-2Gy/次),采用IBDQ-B问卷评估肠道症状,以ΔIBDQ-B第25百分位数为终点,多因素logistic回归分析剂量体积及临床参数。
主要发现
- 分析聚焦于4个中位ΔIBDQ-B>0的问题,仅稀便(ΔIBDQ5≥3)与剂量体积参数相关。
- 按肠管DVH分组:高风险为V20>470cc、V30>245cc、V42>110cc,低风险为其余患者。
- 两变量模型包含高风险DVH形状(OR 9.3)和年龄(保护性,OR 0.94),校准良好(斜率1.003,R2=0.92), bootstrap内部验证稳健。
关键数值与推荐
- 高风险肠管DVH:V20>470cc、V30>245cc、V42>110cc;低风险为不满足任一条件者。
- 稀便终点定义:ΔIBDQ5≥3。
临床怎么用
- 前列腺癌全盆腔调强放疗计划设计时,可参考肠管剂量体积阈值(V20≤470cc、V30≤245cc、V42≤110cc)以降低稀便风险。
- 对年轻患者应尤其关注肠道剂量限制。
局限性
- 原文未报告
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND PURPOSE: Intestinal toxicity is commonly experienced during whole-pelvis intensity-modulated radiotherapy (WPRT) for prostate cancer. The aim of the current study was to assess bowel dose-volume relationships for acute patient-reported intestinal symptoms of patients treated with WPRT for prostate cancer. MATERIALS AND METHODS: Complete data of 206 patients were available; the median dose to pelvic nodes was 51.8Gy (range 50.4-54.4, 1.7-2Gy/fr). Intestinal symptoms were assessed as changes in the Inflammatory Bowel Disease Questionnaire scores relative to the Bowel Domain (IBDQ-B) between baseline and radiotherapy mid-point/end. The 25th percentiles of the most severe worsening from baseline (ΔIBDQ-B) were set as end-points. The impact of bowel loops and sigmoid colon dose-volume/surface parameters as well as selected clinical parameters were investigated using multivariate logistic regression. RESULTS: Analyses were focused on the four questions showing a median ΔIBDQ-B>0. No dose volume/surface parameters were predictive, other than ΔIBDQ5≥3 (loose stools): when grouping patients according to bowel DVHs (high risk: V20>470cc, V30>245cc, V42>110cc; low risk: all the remaining patients), a two-variable model including high-risk DVH-shape (OR: 9.3) and age (protective, OR: 0.94) was assessed. The model showed good calibration (slope: 1.003, R2=0.92) and was found to be robust after bootstrap-based internal validation. CONCLUSIONS: Constraining the bowel loops may reduce the risk of loose stools. The risk is higher for younger patients.
引用
- Sini C, Noris Chiorda B, Gabriele P, et al. Patient-reported intestinal toxicity from whole pelvis intensity-modulated radiotherapy: First quantification of bowel dose-volume effects. Radiother Oncol. 2017. PMID: 28739383. doi:10.1016/j.radonc.2017.07.005
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。